[A newly designed system, "FC-UV-CDDP", and a study of its oncolytic effect].
We devised a fibrin clot (FC) using an ultraviolet (UV)-crosslinking method. To evaluate the in vivo chemotherapeutic effects for cancer chemotherapy with our novel drug delivery system, the anticancer agent cis-platinum (CDDP) was impregnated into each FC and this "FC-UV-CDDP" was intraperitoneally (i.p.) administered to each ascitic hepatoma AH-130 in cancer-bearing rats. Other groups of AH-130 bearing rats, i.p. injected with CDDP or non-treated, served as the controls. We recorded the survival period of each animal and autopsied it at the time of death. All the animals treated with "FC-UV-CDDP" survived for more than 5 weeks and had no retention of ascites. Furthermore, all the surviving rats underwent a challenge with AH-130 cells. Two of 3 repeatedly challenged rats revealed no evidence of recurrence of the cancer and survived for more than 3 months. The control rats died of cachexia with a massive ascites within 2 weeks. Thus, our newly devised "FC-UV-CDDP" system favorably functioned in an experimental cancer model. These data suggested that this oncolytic effect was attributed to the possibility of inducing immune responses against AH-130 as well as to a sustained release of CDDP from FC.
Shindoh
T
T
Dept. of Pathology, School of Allied Health Sciences, Faculty of Medicine, Osaka University.
Matsuura
N
N
Sugitachi
A
A
Saitoh
K
K
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002945:Cisplatin / Q000494:pharmacology*; D016503:Drug Delivery Systems; D015195:Drug Design; D005337:Fibrin; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D051381:Rats
D000970:Antineoplastic Agents; D005337:Fibrin; D002945:Cisplatin